{"id":"azithromycin-1-gram-iv","safety":{"commonSideEffects":[{"rate":"3-5%","effect":"Nausea"},{"rate":"5-7%","effect":"Diarrhea"},{"rate":"2-4%","effect":"Abdominal pain"},{"rate":"1-3%","effect":"Vomiting"},{"rate":"rare","effect":"QT prolongation"},{"rate":"rare","effect":"Hepatotoxicity"},{"rate":"rare","effect":"Clostridium difficile infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Azithromycin is a macrolide antibiotic that binds irreversibly to the bacterial 50S ribosomal subunit, blocking the translocation of peptides and inhibiting protein synthesis. This bacteriostatic action prevents bacterial replication and allows the immune system to clear the infection. It has broad-spectrum activity against many gram-positive and gram-negative bacteria, as well as atypical organisms.","oneSentence":"Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and stopping bacterial growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:28:08.841Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired pneumonia"},{"name":"Acute bacterial sinusitis"},{"name":"Acute otitis media"},{"name":"Pharyngitis/tonsillitis"},{"name":"Uncomplicated skin and soft tissue infections"},{"name":"Sexually transmitted infections (chlamydia, gonorrhea)"}]},"trialDetails":[{"nctId":"NCT05132829","phase":"PHASE4","title":"Azithromycin to Improve Latency in Exam Indicated Cerclage Control Trial","status":"UNKNOWN","sponsor":"Thomas Jefferson University","startDate":"2021-12-20","conditions":"Preterm Birth, Obstetric Labor, Premature, Obstetric Labor Complications","enrollment":50},{"nctId":"NCT04395768","phase":"PHASE2","title":"International ALLIANCE Study of Therapies to Prevent Progression of COVID-19","status":"UNKNOWN","sponsor":"National Institute of Integrative Medicine, Australia","startDate":"2020-09-09","conditions":"COVID19","enrollment":200},{"nctId":"NCT00035347","phase":"PHASE4","title":"Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-01","conditions":"Community-Acquired Pneumonia (CAP)","enrollment":219},{"nctId":"NCT00153634","phase":"NA","title":"Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2004-03","conditions":"Cystic Fibrosis, Chronic Bronchitis","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Azithromycin 1 gram IV","genericName":"Azithromycin 1 gram IV","companyName":"Thomas Jefferson University","companyId":"thomas-jefferson-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Azithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation and stopping bacterial growth. Used for Community-acquired pneumonia, Acute bacterial sinusitis, Acute otitis media.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}